TR-FRET Biosensor for MyBP-C Binding Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current techniques for investigating the role of phosphorylation in myosin binding protein C (MyBP-C) interactions with myosin and actin are labor-intensive, time-consuming, and of low throughput, hindering the search for therapeutic drugs for cardiomyopathies and heart failure.
Innovation Solution
A high-throughput assay using time-resolved fluorescence energy transfer (TR-FRET) with a fluorescent protein biosensor, where a thiol-reactive fluorescent donor probe is placed on the human regulatory light chain of myosin and an acceptor probe on MyBP-C, allowing for the detection of structural changes and binding interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current techniques are used to investigate phosphorylation role in MyBP-C binding, then detailed understanding of binding interactions can be obtained, but the process becomes labor-intensive and low throughput
Solution Approach 1:
The patent replaces traditional mechanical/biochemical binding assays with a fluorescence-based optical detection system. Fluorescent probes are attached to MyBP-C and myosin, and fluorescence resonance energy transfer (FRET) is used to detect binding interactions, eliminating the need for labor-intensive manual operations while maintaining measurement precision.
Solution Approach 2:
The patent introduces phosphorylation-sensitive fluorescent probes that change their fluorescence properties in response to phosphorylation status. This allows the assay to detect both binding interactions and phosphorylation events simultaneously, increasing throughput without sacrificing the detailed understanding of binding mechanisms.
2Measurement precision
If current techniques are used to investigate phosphorylation role in MyBP-C binding, then detailed understanding of binding interactions can be obtained, but the process becomes time-consuming
Solution Approach 1:
The patent replaces time-consuming biochemical assays with real-time fluorescence detection. The FRET-based system provides continuous monitoring of binding interactions, reducing the total assay time while maintaining the ability to detect detailed binding mechanisms and phosphorylation effects.
Solution Approach 2:
The patent enables continuous real-time monitoring of binding interactions through fluorescence detection, rather than requiring discrete time points. This continuous observation reduces the overall assay duration while providing comprehensive information about binding kinetics and phosphorylation effects throughout the interaction process.
3Productivity
If high-throughput screening is implemented, then productivity increases, but measurement precision and reproducibility may be compromised
Solution Approach 1:
The patent uses automated fluorescence plate reader technology to perform high-throughput screening. The optical detection system is inherently more precise and reproducible than manual biochemical assays, and the automation ensures consistent measurement conditions across all compounds screened, maintaining both high throughput and measurement precision.
Solution Approach 2:
The fluorescent probes are designed to automatically report binding events through their fluorescence properties, eliminating the need for complex data processing or manual analysis. The FRET signal provides direct, quantitative measurement of binding interactions, ensuring reproducibility across high-throughput screens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise and reproducible screening of bioactive compounds and determination of the effects of disease mutations in the myosin-MyBP-C protein complex, facilitating the identification of potential therapeutic drugs for cardiomyopathies and heart failure.
Implementation Method 1
time-resolved fluorescence energy transfer (TR-FRET) with a fluorescent protein biosensor, where a thiol-reactive fluorescent donor probe is placed on the human regulatory light chain of myosin and an acceptor probe on MyBP-C, allowing for the detection of structural changes and binding interactions
Data Source
AI summary
N-terminal cardiac myosin-binding protein C (cMyBP-C) domains (C0-C2) bind to thick (myosin) and thin (actin) filaments to facilitate contraction and relaxation of the heart. These interactions are regulated by phosphorylation of the M-domain situated between domains C1 and C2. In cardiomyopathies and heart failure, phosphorylation of cMyBP-C is significantly altered. A current challenge is to understand myosin- and actin-C0-C2 interactions in the context of mutations and phosphorylation states. The combinatorial analysis needed is challenging with current low-throughput assays. Described herein are time-resolved fluorescence resonance energy transfer (TR-FRET) high-throughput assays to meet this need.